Found: 1
Select item for more details and to access through your institution.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 6, p. 1641, doi. 10.1007/s10637-021-01152-z
- By:
- Publication type:
- Article